Abbott Laboratories has been granted a patent for a liquid pharmaceutical formulation suitable for oral administration, containing hydroxychloroquine, glycerin, a carbonate, EDTA, citric acid, and minimal water. The formulation is designed to resist degradation from hydrogen peroxide, maintaining stability under specified conditions. GlobalData’s report on Abbott Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abbott Laboratories, NSAID cancer drugs was a key innovation area identified from patents. Abbott Laboratories's grant share as of June 2024 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12042491B1 outlines a liquid pharmaceutical formulation designed for oral administration, primarily containing hydroxychloroquine (HCQ) in concentrations ranging from 30 mg/ml to 50 mg/ml. The formulation also includes glycerin at levels between 1,000 mg/ml and 1,250 mg/ml, and a carbonate component, which can be selected from various options such as sodium carbonate or potassium carbonate, at concentrations of 0.2 mg/ml to 0.5 mg/ml. Additionally, the formulation incorporates ethylenediaminetetraacetic acid (EDTA) in amounts from 1 mg/ml to 25 mg/ml, citric acid to adjust the pH between 6 and 10, and a maximum of 20 mg/ml of water. Notably, the formulation is characterized by an assay drop of approximately 5% to 20% after seven days at 60°C, indicating its stability under oxidative degradation conditions.
Further claims specify variations of the formulation, including specific assay drop ranges of 10% to 20% and 10% to 15%. The patent also highlights the use of sodium carbonate as the carbonate component, with corresponding assay drop specifications. A specific embodiment of the formulation is detailed, featuring approximately 40 mg/ml of hydroxychloroquine sulfate, 0.35 mg/ml of sodium carbonate, 1,235 mg/ml of glycerin, and 10 mg/ml of EDTA, along with citric acid for pH adjustment and a maximum of 20 mg/ml of water. This formulation aims to provide a stable and effective liquid option for oral administration of hydroxychloroquine, potentially enhancing its therapeutic application.
To know more about GlobalData’s detailed insights on Abbott Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
